Consumption of oxygen: A mitochondrial-generated progression signal of advanced cancer

Cell Death and Disease

Volumn 3, Issue 1, 2012, Pages

  Cook, C C ^a   Kim, A ^a   Terao, S ^b   Gotoh, A ^b   Higuchi, M ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

3 hydroxy 3 methyl glutaryl CoA reductase; Hypoxia; Mitochondrial DNA; Prostate cancer; Ras

Indexed keywords

MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE; OXYGEN; PROTEIN KINASE B; RAS PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL HYPOXIA; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL GENOME; MITOCHONDRION; NONHUMAN; ONCOGENE K RAS; OXYGEN CONSUMPTION; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; AGED; APOPTOSIS; BIOSYNTHESIS; BREAST TUMOR; CANCER STAGING; DISEASE COURSE; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

AGED; APOPTOSIS; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA, MITOCHONDRIAL; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MALE; MIDDLE AGED; MITOCHONDRIA; NEOPLASM STAGING; OXYGEN; OXYGEN CONSUMPTION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84856836080     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2011.141     Document Type: Article

References (40)

1. American Cancer Society. Cancer Facts & Figures. ACS: Atlanta, GA, 2009.
2. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J et al. Sequence and organization of the human mitochondrial genome. Nature 1981; 290: 457-465. (Pubitemid 11159074)
3. Carew JS, Huang P. Mitochondrial defects in cancer. Molecular Cancer 2002; 1: 1-12.
4. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008; 320: 661-664. (Pubitemid 351928347)
5. Chen JZ, Gokden N, Greene GF, Mukunyadzi P, Kadlubar FF. Extensive somatic mitochondrial mutations in primary prostate cancer using laser capture microdissection. Cancer Res 2002; 62: 6470-6474. (Pubitemid 35364109)
6. Barthelemy C, de Baulny HO, Lombes A. D-loop mutations in mitochondrial DNA: link with mitochondrial DNA depletion? Human Genetics 2002; 110: 479-487. (Pubitemid 36074994)
7. Chandel NS, Schumacker PT. Cells depleted of mitochondrial DNA (rho0) yield insight into physiological mechanisms. FEBS Letters 1999; 454: 173-176. (Pubitemid 29304594)
8. Higuchi M, Aggarwal BB, Yeh ET. Activation of CPP32-like protease in tumor necrosis factor-induced apoptosis is dependent on mitochondrial function. J Clin Invest 1997; 99: 1751-1758. (Pubitemid 27163827)
9. Higuchi M, Kudo T, Suzuki S, Evans TT, Sasaki R, Wada Y et al. Mitochondrial DNA determines androgen dependence in prostate cancer cell lines. Oncogene 2006; 25: 1437-1445. (Pubitemid 43361929)
10. Naito A, Cook CC, Mizumachi T, Wang M, Xie CH, Evans TT et al. Progressive tumor features accompany epithelial-mesenchymal transition induced in mitochondrial DNA-depleted cells. Cancer Science 2008; 99: 1584-1588.
11. Xie CH, Naito A, Mizumachi T, Evans TT, Douglas MG, Cooney CA et al. Mitochondrial regulation of cancer associated nuclear DNA methylation. Biochem Biophys Res Commun 2007; 364: 656-661. (Pubitemid 350026513)
12. Nishimura G, Proske RJ, Doyama H, Higuchi M. Regulation of apoptosis by respiration: cytochrome c release by respiratory substrates. FEBS Lett 2001; 505: 399-404. (Pubitemid 32905485)
13. Suzuki S, Naito A, Asano T, Evans T, Reddy S, Higuchi M. Constitutive Activation of AKT Pathway Inhibits TNF-induced Apoptosis in Mitochondrial DNA-Deficient human myelogenous leukemia ML-1a. Cancer Lett 2008; 268: 31-37.
14. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochem Biophys Acta 2007; 1773: 1263-1284. (Pubitemid 47125967)
15. Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ. Activation of mitogenactivated protein kinase associated with prostate cancer progression. Cancer Res 1999; 59: 279-284. (Pubitemid 29048852)
16. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, Abate-Shen C. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgenindependent prostate cancer. Proc Natl Acad Sci USA 2006; 103: 14477-14482. (Pubitemid 44484775)
17. Bakin RE, Gioeli D, Bissonette EA, Weber MJ. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 2003; 63: 1975-80. (Pubitemid 36460866)
18. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L et al. The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980; 37: 115-132.
19. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgenindependent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994; 57: 406-412. (Pubitemid 24168617)
20. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17: 16-23. (Pubitemid 9239413)
21. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978; 21: 274-281. (Pubitemid 8283045)
22. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51: 1409-1416.
23. Zhang XF, Settleman J, Kyriakis JM, Takeuchi-Suzuki E, Elledge SJ, Marshall MS et al. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 1993; 364: 308-313. (Pubitemid 23265270)
24. Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ et al. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 1994; 266: 1719-1723.
25. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994; 370: 527-532. (Pubitemid 24264918)
26. Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H et al. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res 2004; 10: 2082-2089. (Pubitemid 38375570)
27. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T et al. An oncogenetumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010; 16: 286-294.
28. Jancik S, Drabek J, Radzioch D, Hajduch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010; 2010: 150960.
29. Konstantinopoulos PA, Karamouzis MV, AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nature Reviews. Drug Discovery 2007; 6: 541-555. (Pubitemid 47019443)
30. Willumsen BM, Christensen A, Hubbert NL, Papageorge AG, Lowy DR. The p21 ras C-terminus is required for transformation and membrane association. Nature 1984; 310: 583-586. (Pubitemid 14053901)
31. Manne V, Roberts D, Tobin A, O'Rourke E, De Virgilio M, Meyers C et al. Identification and preliminary characterization of protein-cysteine farnesyltransferase. Proc Natl Acad Sci USA 1990; 87: 7541-7545. (Pubitemid 20341752)
32. Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 1990; 62: 81-88.
33. Chang TY, Chang CC, Ohgami N, Yamauchi Y. Cholesterol sensing, trafficking, and esterification. Annu Rev Cell Dev Biol 2006; 22: 129-157.
34. Song BL, Javitt NB, DeBose-Boyd RA. Insig-mediated degradation of HMG CoA reductase stimulated by lanosterol, an intermediate in the synthesis of cholesterol. Cell Metabolism 2005; 1: 179-189. (Pubitemid 43960599)
35. Nguyen AD, McDonald JG, Bruick RK, DeBose-Boyd RA. Hypoxia stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase through accumulation of lanosterol and hypoxia-inducible factor-mediated induction of insigs. J Biol Chem 2007; 282: 27436-27446. (Pubitemid 47501948)
36. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002; 50: 222-235. (Pubitemid 34184661)
37. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M et al. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 2000; 44: 91-103. (Pubitemid 30419183)
38. Higuchi M, Manna SK, Sasaki R, Aggarwal BB. Regulation of the activation of nuclear factor kappaB by mitochondrial respiratory function: evidence for the reactive oxygen speciesdependent and -independent pathways. Antioxidants Redox Signaling 2002; 4: 945-955. (Pubitemid 36042470)
39. Mizumachi T, Muskhelishvili L, Naito A, Furusawa J, Fan CY, Siegel ER et al. Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cells. Prostate 2008; 68: 408-417. (Pubitemid 351342646)
40. Terada Y, Kobayashi T, Kuwana H, Tanaka H, Inoshita S, Kuwahara M et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogenactivated protein kinase 1/2, cyclin D1, and cyclin A. J Am Soc Nephrol 2005; 16: 2296-2305. (Pubitemid 41725047)